Illumina dans l'actualité
Solutions technologiques d'analyse génétique
Tamtam a trouvé 20 articles récents sur Illumina.
- Illumina (NASDAQ: ILMN) CLO grants may pay up to 250% of target shares
- Advancing whole-genome sequencing with long-range data
- Evaluating new approaches for rare disease research
- Illumina (ILMN) Following Novacyt Deal Has Investors Asking If The Stock Looks Fully Valued
- Illumina Inc. stock underperforms Wednesday when compared to competitors
- This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
- Illumina Insider Sells $57M in Stock as ILMN Prepares to Join S&P 500
- Palani Kumaresan: Roche Diagnostics Is Ramping Up—Should Illumina Be Worried?
- Illumina: Priced For Perfection It Hasn't Earned Yet (NASDAQ:ILMN)
- Bloom Energy, Everpure, Illumina to Join S&P 500 in September Rebalance
- A Look at Illumina Inc (ILMN) After 3.3% Decline -- GF Value $132.76 vs Price $211.06
- ILMN Stock Keeps Climbing. Should You Climb On?
- Partnership Deal And Rating Upgrade Altering The Investment Case For Illumina (ILMN)?
- Illumina and Everpure to Join S&P 500 in September Rebalancing: What it Means for Investors
- Illumina, a "pick company" of deoxyribonucleic acid (DNA) research, succeeded in re-establishing it
- How Illumina’s (ILMN) Novacyt Collaboration Framework Could Shape Its Clinical Sequencing Strategy
- The Trade Desk to leave S&P 500 as Bloom Energy, Everpure, Illumina join index
- Bloom Energy, Illumina and Everpure set to join S&P 500 before Sept. 21 open
- Illumina (ILMN) Stock Looks Priced For Growth More Than Value
- Bloom Energy, Illumina, and Everpure Are Joining the S&P 500. These 3 Stocks Are Leaving.
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Illumina ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires